Brv China-Backed Global Leading Exoskeleton Company Roboct Secures Rmb100 Million Series A+ Financing
Brv China-Backed Global Leading Exoskeleton Company Roboct Secures Rmb100 Million Series A+ Financing
04/12/22, 7:14 AM
Money raised
¥100 million
Round Type
series a
Hangzhou RoboCT Technology Development Co., Ltd., a global leading exoskeleton company, recently completed RMB100 million series A+ financing led by Fortune Capital and followed by Essence Securities, Poly Capital, and existing investor Blue Run Ventures China (BRV China). The new round of financing will be used to strengthen RoboCT's operational and commercialization capabilities and expand its global footprint.
Company Info
Additional Info
Hangzhou RoboCT Technological Development Co.,Ltd. is dedicated to providing the disabled, the elderly and medical rehabilitation institutes with intelligent rehabilitation devices, rehabilitation assistance and smart solutions through by combining Artificial Intelligence and robotic technology with data analysis and cloud computing. It also involves the research and product development of exoskeleton technology in several fields such as entertainment, industry and sports. RoboCT has applied for over 100 intellectual IPRS and has received more than 20 awards across different fields. RoboCT was the first in China to obtain the NMPA (National Medical Products Administration) registration certificate for lower-limb exoskeleton robots for central neuropathy. For further information, please visit https://www.roboct-global.com/.
SOURCE BRV China